Skip to main content
. Author manuscript; available in PMC: 2011 Apr 10.
Published in final edited form as: Arterioscler Thromb Vasc Biol. 2009 Jun 11;29(9):1376–1382. doi: 10.1161/ATVBAHA.109.191585

Figure 4.

Figure 4

Figure 4

Figure 4

Overexpression of the dominant-negative PKD2 mutant or knockdown of PKD2 expression by siRNA blocks lysoPC-induced monocyte migration. A, Effect of overexpression of dominant-negative PKD2 on lysoPC-induced THP-1 cell migration. After transfection, cells were cultured in growth medium for 2 days and then treated with or without lysoPC (15 μmol/L) for 3 h, and cell migration was determined as described in the Methods section. Data are means ± SE from 6 experiments. *P<0.05 vs control. B, Effect of PKD2 siRNA on lysoPC-induced THP-1 cell migration. The cells, mock transfected or transfected with either nonsilencing siRNA (control) or PKD2 siRNA, were treated with or without lysoPC (15 μmol/L) for 3 h in the migration assay. Data are means ± SE from 8 experiments. *P<0.05 vs control siRNA. C, Effect of PKD2 siRNA on lysoPC-induced monocyte migration. The cells, mock transfected or transfected with either nonsilencing siRNA (control) or PKD2 siRNA, were treated with or without lysoPC (15 μmol/L) for 3 h in the migration assay. Data are means ± SE from 3 experiments. *P<0.05 vs control siRNA.